Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07480525

Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder

The goal of this project is to quantify the effectiveness and safety of escitalopram oxalate oral solution in the treatment of first-episode, drug-naïve patients with major depressive disorder, and to explore the mechanisms underlying its antidepressant effects using multi-omics approaches. By integrating clinical, cognitive, laboratory, imaging, genetic, and environmental data, the study aims to identify patient subgroups who are most likely to benefit from escitalopram, thereby promoting individualized and precision treatment for depression.

This multicenter, prospective, single-arm intervention study will enroll 200 adults aged 18-65 years with major depressive disorder, who will receive escitalopram oxalate oral solution for 8 weeks. Depressive symptoms, cognitive function, and adverse events will be assessed at baseline, during treatment, and after 8 weeks of treatment to evaluate efficacy and safety. Escitalopram blood concentrations will be measured at week 4 to monitor treatment adherence and support safety evaluation. Through comprehensive data collection and multimodal analysis, this project seeks to clarify the biological mechanisms of escitalopram and provide evidence to guide more precise clinical use of antidepressant therapy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Depression - Major Depressive Disorder Behavior Behavioral Symptoms Depression

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Peking University Sixth Hostipal, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-65 years (including 18 and 65), no gender restriction, Han Chinese ethnicity.
  • Meets the diagnostic criteria for depressive disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), confirmed by the Mini-International Neuropsychiatric Interview, version 5.0 (MINI).
  • Outpatients or inpatients; Hamilton Depression Rating Scale-17 items (HAMD-17) score ≥17; Hypomania Checklist-32 (HCL-32) score ≤13; and Clinical Global Impressions-Severity (CGI-S) score ≥4.
  • First depressive episode (duration ≤3 months), with no use of antidepressants or other psychotropic medications in the past 3 months.
  • Written informed consent obtained from the patient.

Exclusion criteria

  • Meet DSM-IV diagnostic criteria other mental disorders, including schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, obsessive-compulsive disorder, etc..
  • Individuals with intellectual disabilities or who are unable to cooperate for other reasons, or those lacking or having incomplete civil capacity during the onset of illness;
  • Suffering from neurological or organic brain diseases (such as stroke, cerebral hemorrhage, brain tumors, Parkinson's disease, epilepsy, etc.) and a history of severe traumatic brain injury;
  • Have attempted suicide within the past 3 months, or currently present a high suicide risk, defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) item 10 score ≥5.
  • Are pregnant or breastfeeding, cannot use reliable contraception during the study, or plan to conceive (or impregnate a partner) within 3 months after study initiation.
  • Have known allergies to escitalopram oxalate or its excipients.
  • Are currently taking medications that may interfere with the evaluation of escitalopram efficacy.
  • Have participated in another drug clinical trial within the past 3 months.
  • Have contraindications to MRI scanning, such as metal implants or claustrophobia.
  • Considered unsuitable for study participation by the investigators for any other reason.

Treatment and study plan

Escitalopram (Oral antidepressant)

Drug

Participants will receive escitalopram oral solution as open-label monotherapy.

Primary outcomes

  1. Change from baseline in Hamilton Depression Rating Scale (HAMD)

    Time frame: Week 4 and 8 of treatment duration

    The outcome is assessed by 17-item Hamilton Depression Rating Scale (HAMD-17) Scale. Total HAMD scores range from 0 to 24, with higher scores indicating more severe depressive symptoms. The change of HAMD from baseline to 8-week (after intervention) was used as the primary outcome.

Secondary outcomes

  1. Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)

    Time frame: Week 4 and 8 of treatment duration

  2. Response to treatment

    Time frame: Week 4 and 8 of treatment duration

    The reduction rate of HAMD-17 or MADRS score was ≥50%

  3. Clinical Global Impression-Severity of Illness (CGI-S)

    Time frame: Baseline; Week 4 and 8 of treatment duration

  4. Change from baseline in C-BCT score

    Time frame: Week 4 and 8 of treatment duration

  5. Change from baseline in Hamilton Anxiety Rating Scale (HAMA)

    Time frame: Week 4 and 8 of treatment duration

  6. Treatment Emergent Symptom Scale (TESS)

    Time frame: Baseline; Week 4 and 8 of treatment duration

  7. Escitalopram Therapeutic drug monitoring

    Time frame: Week 4 of treatment duration

  8. Change from baseline in Snaith-Hamilton Pleasure Scale (SHAPS)

    Time frame: Week 4 and 8 of treatment duration

  9. The Temporal Experience of Pleasure Scale (TEPS)

    Time frame: Week 4 and 8 of treatment duration

  10. Childhood Trauma Questionnaire (CTQ)

    Time frame: Baseline

  11. Change from baseline in Ruminative Responses Scale (RRS)

    Time frame: Week 4 and 8 of treatment duration

  12. Change from baseline in Pittsburgh Sleep Quality Index (PSQI)

    Time frame: Week 4 and 8 of treatment duration

  13. Change from baseline in Connor-Davidson Resilience Scale (CD-RISC)

    Time frame: Week 4 and 8 of treatment duration

  14. Biomarkers level

    Time frame: Week 0 and 8 of treatment duration

    CRP, IL-1β, TNF-α, IL-6, IL-8, IL-10 and other immune factors, irisin, neurotrophic factor BDNF, vascular endothelial growth factor VEGF, and insulin growth factor IGF-1, NLRP3, CXCL8, CXCL3, CCL5, etc

  15. Brain imaging features

    Time frame: Week 0 and 8 of treatment duration

    Acquisition was performed by magnetic resonance imaging

Study contacts

Contact information is provided by the study sponsor or research team.

Tong Yu

CONTACT

[email protected]

86-010-82805307

Weihua Yue

CONTACT

[email protected]

86-010-82805307

Sponsors and collaborators

Lead sponsor

Peking University

Other

Collaborators

  • First Hospital of China Medical University
  • Hebei Provincial Mental Health Center
  • Shandong Mental Health Center
  • The First Hospital of Hebei Medical University

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 18, 2026
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.